CellCentric have achieved a major milestone as CCS1477 publishes in Cancer Discovery: Targeting p300/CBP axis in lethal prostate cancer.
This is the result of a great collaboration with the Institute of Cancer Research, London and Sidney Kimmel Cancer Centre (TJU), Philadelphia, with support from the Prostate Cancer Foundation.
“This has been a massive team effort to get to here, a key milestone. Thank you to all our collaborative scientists, CROs, suppliers, service providers, advisors, consultants, partner hospitals and funders” – Will West, CEO CellCentric
For more details please see CellCentric’s press release.